azficel-T (Laviv)
Jump to navigation
Jump to search
Indications
- improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. Conraindications:
- achondroplasia
- ataxia-telangiectasia
- Ehlers-Danlos syndrome
- epidermolysis bullosa
- hypertrophic scarring or keloid formation
- Marfan syndrome
- osteogenesis imperfecta
- skin cancer
- allergy to certain antibiotics (gentamicin, amphotericin), dimethyl sulfoxide (DMSO), or any bovine products
- skin infections of the face
- immunosuppression
- hemorrhagic diathesis
- Herpes labialis
- leukocytoclastic vasculitis[3]
Dosage
Mechanism of action
More general terms
References
- ↑ LAVIV (azficel-T) Demonstrates Improvement in Acne Scarring http://www.drugs.com/clinical_trials/laviv-azficel-t-demonstrates-improvement-acne-scarring-12597.html
- ↑ FDA: Vaccines, Blood & Biologics Autologous Fibroblasts http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm260485.htm
- ↑ 3.0 3.1 Azficel-T (Intradermal Route) Mayo Clinic http://www.mayoclinic.com/health/drug-information/DR603475
- ↑ Smith SR et al. A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles. Dermatol Surg 2012 Jul; 38:1234 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22409385